Back

Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy

26 August 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 2 - Coronary artery disease: from bench to bedside Thrombosis and coagulation ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Gerald Chi

Harvard Medical School, Boston (United States of America)

71 More presentations in this session

Presentation thumbnail
Proprotein convertase subtilisin/kexin type 9 (PCSK9), platelet activation and risk of cardiovascular events in atrial fibrillation
Professor P. Pignatelli Spinazzola (Rome, IT)
Abstract Slides
Presentation thumbnail
Factor V Leiden related risk of thromboembolic and bleeding complications in patients with established coronary heart disease.
Doctor B. Mahmoodi (Rotterdam, NL)
Abstract Slides
Presentation thumbnail
Factor V Leiden and prothrombin G20210A mutations in patients with premature myocardial infarction.
Professor L. Rallidis (Athens, GR)
Abstract Slides
Presentation thumbnail
Angiographic and hemodynamic modifications of Myocardial Bridge during supine bicycle exercise
Doctor J. Adjedj (Saint Laurent du Var, FR)
Abstract Slides
Presentation thumbnail
Intracoronary electrocardiographic parameters predict mortality rates at mid-term follow-up (up to 60 months) after stenting coronary bifurcation lesions
Professor K. Karamfiloff (Sofia, BG)
Abstract Slides

Access the full session

Session thumbnail
Poster session 2 - Coronary artery disease: from bench to bedside

The Event

Event poster

ESC Congress 2017

26 August - 30 August 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources